Ascendis Pharma A/S’s (ASND) “Buy” Rating Reiterated at TD Cowen

TD Cowen restated their buy rating on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a report released on Wednesday morning,Benzinga reports. TD Cowen currently has a $325.00 target price on the biotechnology company’s stock.

Several other equities analysts have also recently weighed in on the company. Wolfe Research initiated coverage on Ascendis Pharma A/S in a research note on Tuesday, November 18th. They set a “peer perform” rating and a $255.00 target price on the stock. Wall Street Zen cut shares of Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Ascendis Pharma A/S in a research report on Wednesday, November 26th. JPMorgan Chase & Co. increased their target price on shares of Ascendis Pharma A/S from $260.00 to $264.00 and gave the stock an “overweight” rating in a research report on Thursday, October 9th. Finally, Raymond James Financial started coverage on shares of Ascendis Pharma A/S in a research note on Friday, October 17th. They set a “strong-buy” rating and a $271.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Ascendis Pharma A/S presently has a consensus rating of “Buy” and a consensus target price of $262.69.

Ascendis Pharma A/S Stock Down 2.8%

Shares of NASDAQ:ASND opened at $202.99 on Wednesday. The company’s fifty day moving average is $207.54 and its two-hundred day moving average is $196.46. The company has a market cap of $12.58 billion, a P/E ratio of -45.72, a price-to-earnings-growth ratio of 1.09 and a beta of 0.46. Ascendis Pharma A/S has a 12-month low of $118.03 and a 12-month high of $229.94.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Thursday, November 13th. The biotechnology company reported ($1.17) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.76). The firm had revenue of $250.71 million during the quarter, compared to analyst estimates of $246.91 million. Equities research analysts anticipate that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Institutional Trading of Ascendis Pharma A/S

Several large investors have recently added to or reduced their stakes in ASND. Avoro Capital Advisors LLC raised its holdings in shares of Ascendis Pharma A/S by 2.6% during the 3rd quarter. Avoro Capital Advisors LLC now owns 5,110,000 shares of the biotechnology company’s stock valued at $1,015,919,000 after purchasing an additional 130,000 shares in the last quarter. Capital International Investors increased its position in Ascendis Pharma A/S by 0.4% during the third quarter. Capital International Investors now owns 3,060,616 shares of the biotechnology company’s stock worth $608,481,000 after buying an additional 13,685 shares during the last quarter. Massachusetts Financial Services Co. MA raised its holdings in Ascendis Pharma A/S by 1.3% during the second quarter. Massachusetts Financial Services Co. MA now owns 1,901,843 shares of the biotechnology company’s stock valued at $328,258,000 after buying an additional 23,926 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Ascendis Pharma A/S by 95.9% in the third quarter. Wellington Management Group LLP now owns 1,798,931 shares of the biotechnology company’s stock worth $357,645,000 after buying an additional 880,836 shares during the last quarter. Finally, Perceptive Advisors LLC acquired a new stake in shares of Ascendis Pharma A/S in the second quarter worth about $166,367,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.